PhRMA "Re-Repositioning"? Working Group Studying Rx Affordability Ahead Of Annual Meeting
This article was originally published in The Pink Sheet Daily
Pfizer exec Katen is overseeing group studying access and affordability issues. Association hopes to build on spirit of "repositioning" work that led to marketing guidelines in 2002.
You may also be interested in...
Michelle Easton will oversee advocacy efforts on a wide range of programs and will work closely with health care partners in the newly created role of VP-group on affordability & access. She was a legislative assistant for former Rep. (now PhRMA CEO) Tauzin before working in former Sen. Breaux’s office for eight years.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.